학술논문
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Document Type
Letter
Author
Source
Subject
*THERAPEUTIC use of antineoplastic agents
*ETOPOSIDE
*DRUG efficacy
*TOPOTECAN
*CONFIDENCE intervals
*SMALL cell carcinoma
*FISHER exact test
*PLATINUM
*TREATMENT effectiveness
*SURVIVAL rate
*SURVIVAL analysis (Biometry)
*KAPLAN-Meier estimator
*DESCRIPTIVE statistics
*PROGRESSION-free survival
*OVERALL survival
*DRUG toxicity
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0284-186X
Abstract
The article focuses on a randomized phase III trial comparing first-line platinum-based treatments for extended stage small cell lung cancer. Topics include the historical treatment approach, the trial methodology comparing topotecan/cisplatin with etoposide/carboplatin, and the final results indicating no significant difference in overall survival or progression-free survival between the treatments, despite variations in hematological toxicity.